-ine
Alkaloids and other nitrogen-containing bases (a general chemical ending).
- Drugs ending in -ine: 487
- Approved somewhere: 202
- With a US drug page: 138
- Stem
- -ine
- Class
- Alkaloids and other nitrogen-containing bases (a general chemical ending)
Approved and clinical-stage drugs in ChEMBL whose names ending in -ine, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Acetophenazine | Approved | DRD2 | Dopamine D2 receptor antagonist |
| Acetylcholine | Approved | CHRM3 | Muscarinic acetylcholine receptor M3 agonist |
| Adenosine | Approved | Adenosine receptor | Adenosine receptor agonist |
| Altretamine | Approved | DNA | DNA inhibitor |
| Amifostine | Approved | — | Reactive metabolite scavenging agent |
| Arbutamine | Approved | — | — |
| Arginine hydrochloride | Approved | — | — |
| Bedaquiline | Approved | ATP synthase | ATP synthase inhibitor |
| Benzphetamine | Approved | SLC6A2, SLC18A2 | Norepinephrine transporter releasing agent |
| Betaine | Approved | BHMT, BHMT2 | Betaine-homocysteine S-methyltransferase substrate |
| Bromocriptine | Approved | D2-like dopamine receptor | D2-like dopamine receptor agonist |
| Bromodiphenhydramine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Brompheniramine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Butenafine | Approved | Squalene monooxygenase | Squalene monooxygenase inhibitor |
| Cabergoline | Approved | DRD2 | Dopamine D2 receptor agonist |
| Caffeine | Approved | Adenosine receptor | Adenosine receptor antagonist |
| Carbinoxamine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Cariprazine | Approved | DRD3, DRD2 | Dopamine D3 receptor modulator |
| Cephradine | Approved | Bacterial penicillin-binding protein | Bacterial penicillin-binding protein inhibitor |
| Cholestyramine | Approved | Bile acids | Bile acids sequestering agent |
| Clofazimine | Approved | DNA | DNA inhibitor |
| Codeine | Approved | Opioid receptors; mu/kappa/delta | Opioid receptors; mu/kappa/delta agonist |
| Colchicine | Approved | Tubulin | Tubulin inhibitor |
| Cyclobenzaprine | Approved | HTR2A, HTR2C | Serotonin 2a (5-HT2a) receptor antagonist |
| Cyclosporine | Approved | PPIA | Cyclophilin A modulator |
| Cysteamine | Approved | Cystine | Cystine reducing agent |
| Dacarbazine | Approved | DNA | DNA inhibitor |
| Dalfampridine | Approved | Voltage-gated potassium channel | Voltage-gated potassium channel blocker |
| Deferoxamine | Approved | Iron | Iron chelating agent |
| Delavirdine | Approved | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Deserpidine | Approved | SLC18A2 | Synaptic vesicular amine transporter inhibitor |
| Dexbrompheniramine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Dexmedetomidine | Approved | Adrenergic receptor alpha-2 | Adrenergic receptor alpha-2 agonist |
| Dextrothyroxine | Approved | THRA, THRB | Thyroid hormone receptor agonist |
| Dezocine | Approved | OPRM1, OPRK1 | Mu opioid receptor partial agonist |
| Dicyclomine | Approved | CHRM3, CHRM1 | Muscarinic acetylcholine receptor M3 antagonist |
| Didanosine | Approved | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Diethylcarbamazine | Approved | Nematode GABA-A receptor | Nematode GABA-A receptor positive modulator |
| Dihydroergotamine | Approved | HTR1D | Serotonin 1d (5-HT1d) receptor agonist |
| Diphenhydramine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Diphenylpyraline | Approved | HRH1 | Histamine H1 receptor antagonist |
| Dobutamine | Approved | ADRB1, ADRB2 | Beta-1 adrenergic receptor agonist |
| Dyphylline | Approved | Phosphodiesterase 4, PDE3A | Phosphodiesterase 4 inhibitor |
| Eflornithine | Approved | ODC1 | Ornithine decarboxylase inhibitor |
| Epinephrine | Approved | Adrenergic receptor | Adrenergic receptor agonist |
| Esketamine | Approved | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor negative allosteric modulator |
| Ethanolamine oleate | Approved | Calcium | Calcium chelating agent |
| Ethopropazine | Approved | CHRM1 | Muscarinic acetylcholine receptor M1 antagonist |
| Fenfluramine | Approved | HTR1D, HTR2C, SIGMAR1 | Serotonin 1d (5-HT1d) receptor agonist |
| Fesoterodine | Approved | CHRM3, CHRM2 | Muscarinic acetylcholine receptor M3 antagonist |
| Fexofenadine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Flucytosine | Approved | TMP1 | Thymidylate synthase inhibitor |
| Fluphenazine | Approved | DRD2 | Dopamine D2 receptor antagonist |
| Fluvoxamine | Approved | SLC6A4 | Serotonin transporter inhibitor |
| Galantamine | Approved | ACHE | Acetylcholinesterase inhibitor |
| Halofantrine | Approved | Ferriprotoporphyrin IX | Ferriprotoporphyrin IX inhibitor |
| Histamine | Approved | HRH1 | Histamine H1 receptor agonist |
| Levacetylleucine | Approved | — | Unknown |
| Levocarnitine | Approved | — | — |
| Levomepromazine | Approved | D2-like dopamine receptor | D2-like dopamine receptor antagonist |
| Levothyroxine | Approved | THRA, THRB | Thyroid hormone receptor agonist |
| Liothyronine | Approved | THRA, THRB | Thyroid hormone receptor agonist |
| Lisdexamfetamine | Approved | SLC6A3, SLC6A2, SLC18A2 | Dopamine transporter releasing agent |
| Lofexidine | Approved | Adrenergic receptor alpha-2 | Adrenergic receptor alpha-2 agonist |
| Mecamylamine | Approved | CHRNA3, CHRNB4 | Neuronal acetylcholine receptor; alpha3/beta4 negative allosteric modulator |
| Mechlorethamine | Approved | DNA | DNA inhibitor |
| Mephentermine | Approved | Adrenergic receptor | Adrenergic receptor agonist |
| Mesalamine | Approved | ALOX5, PPARG, PTGS1, PTGS2 | Arachidonate 5-lipoxygenase inhibitor |
| Mesoridazine | Approved | DRD2, HTR2A | Dopamine D2 receptor antagonist |
| Methacholine | Approved | CHRM3 | Muscarinic acetylcholine receptor M3 agonist |
| Methamphetamine | Approved | Monoamine transporter | Monoamine transporter inhibitor |
| Methantheline | Approved | HRH2 | Histamine H2 receptor antagonist |
| Methoxamine | Approved | Adrenergic receptor alpha-1 | Adrenergic receptor alpha-1 agonist |
| Methylergonovine | Approved | HTR2B, DRD1 | Serotonin 2b (5-HT2b) receptor partial agonist |
| Metyrosine | Approved | TH | Tyrosine 3-hydroxylase inhibitor |
| Mexiletine | Approved | Sodium channel alpha subunit | Sodium channel alpha subunit blocker |
| Naftifine | Approved | Squalene monooxygenase | Squalene monooxygenase inhibitor |
| Olsalazine | Approved | ALOX5, PPARG, PTGS1, PTGS2 | Arachidonate 5-lipoxygenase inhibitor |
| Omacetaxine mepesuccinate | Approved | — | Protein synthesis inhibitor |
| Oxyphencyclimine | Approved | CHRM3, CHRM1 | Muscarinic acetylcholine receptor M3 antagonist |
| Pargyline | Approved | MAOA, MAOB | Monoamine oxidase inhibitor |
| Pemoline | Approved | — | Unknown |
| Penicillamine | Approved | Copper | Copper chelating agent |
| Perphenazine | Approved | DRD2 | Dopamine D2 receptor antagonist |
| Phendimetrazine | Approved | SLC6A3, SLC6A2 | Dopamine transporter inhibitor |
| Phenelzine | Approved | MAOA, MAOB | Monoamine oxidase inhibitor |
| Phenoxybenzamine | Approved | Adrenergic receptor alpha | Adrenergic receptor alpha antagonist |
| Phentermine | Approved | SLC6A2 | Norepinephrine transporter releasing agent |
| Phentolamine | Approved | Adrenergic receptor alpha | Adrenergic receptor alpha antagonist |
| Phenylephrine | Approved | Adrenergic receptor alpha-1 | Adrenergic receptor alpha-1 agonist |
| Piperazine | Approved | — | — |
| Procarbazine | Approved | DNA | DNA inhibitor |
| Promazine | Approved | HTR2A, D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor antagonist |
| Promethazine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Propantheline | Approved | CHRM3, CHRM1, CHRM2 | Muscarinic acetylcholine receptor M3 antagonist |
| Pyrimethamine | Approved | Bifunctional dihydrofolate reductase-thymidylate synthase | Dihydrofolate reductase inhibitor |
| Quinine | Approved | Ferriprotoporphyrin IX | Ferriprotoporphyrin IX inhibitor |
| Ranolazine | Approved | SCN5A, SCN4A | Sodium channel protein type V alpha subunit blocker |
| Rescinnamine | Approved | SLC18A2 | Synaptic vesicular amine transporter inhibitor |
| Rotigotine | Approved | D2-like dopamine receptor | D2-like dopamine receptor agonist |
| Scopolamine | Approved | CHRM1 | Muscarinic acetylcholine receptor M1 antagonist |
| Sibutramine | Approved | Monoamine transporter | Monoamine transporter inhibitor |
| Terbutaline | Approved | ADRB2 | Beta-2 adrenergic receptor agonist |
| Tetrabenazine | Approved | SLC18A2 | Synaptic vesicular amine transporter inhibitor |
| Thioguanine | Approved | IMPDH1, IMPDH2, DNA | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor |
| Ticlopidine | Approved | P2RY12 | Purinergic receptor P2Y12 antagonist |
| Tolterodine | Approved | CHRM3, CHRM2 | Muscarinic acetylcholine receptor M3 antagonist |
| Tranylcypromine | Approved | MAOA, MAOB | Monoamine oxidase inhibitor |
| Trientine | Approved | Copper | Copper chelating agent |
| Trifluoperazine | Approved | HTR2A, HTR2C, D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor antagonist |
| Triprolidine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Tromethamine | Approved | — | Unknown |
| Valbenazine | Approved | SLC18A2 | Synaptic vesicular amine transporter inhibitor |
| Viloxazine | Approved | SLC6A2 | Norepinephrine transporter inhibitor |
| Arginine | Phase 3 | — | — |
| Centanafadine | Phase 3 | Monoamine transporter | Monoamine transporter inhibitor |
| Doxylamine | Phase 3 | HRH1 | Histamine H1 receptor antagonist |
| Fluphenazine enanthate | Phase 3 | DRD2 | Dopamine D2 receptor antagonist |
| Glycine | Phase 3 | — | — |
| Ketamine | Phase 3 | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor negative allosteric modulator |
| Paltusotine | Phase 3 | SSTR2 | Somatostatin receptor 2 agonist |
| Uridine triacetate | Phase 3 | — | Unknown |
| Fluphenazine decanoate | Phase 2 | DRD2 | Dopamine D2 receptor antagonist |
| Adenosine phosphate | Phase 1 | — | Unknown |
| Carphenazine | — | HTR2A, HTR2C, DRD2 | Serotonin 2a (5-HT2a) receptor antagonist |
| Chloroxine | — | DNA | DNA inhibitor |
| Cryptenamine acetates | — | — | Unknown |
| Cryptenamine tannates | — | — | Unknown |
| Cycrimine | — | CHRM1 | Muscarinic acetylcholine receptor M1 antagonist |
| Dyclonine | — | Sodium channel alpha subunit | Sodium channel alpha subunit blocker |
| Hydroxyamphetamine | — | Adrenergic receptor | Adrenergic receptor agonist |
| Methscopolamine | — | CHRM3, CHRM1 | Muscarinic acetylcholine receptor M3 antagonist |
| Phenmetrazine | — | SLC6A3, SLC6A2 | Dopamine transporter inhibitor |
| Piperacetazine | — | DRD2 | Dopamine D2 receptor antagonist |
| Propiomazine | — | HRH1 | Histamine H1 receptor antagonist |
| Protamine sulfate | — | Heparin | Heparin inhibitor |
| Theophylline glycinate | — | Phosphodiesterase 4, PDE3A, PDE3B, Adenosine receptor | Phosphodiesterase 4 inhibitor |
| Tubocurarine | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Acetylcarnitine | Approved | — | Unknown |
| Agomelatine | Approved | MTNR1A, MTNR1B, HTR2C | Melatonin receptor agonist |
| Almitrine | Approved | — | Unknown |
| Amifampridine | Approved | Voltage-gated potassium channel | Voltage-gated potassium channel blocker |
| Amineptine | Approved | DRD1, DRD2 | Dopamine D1 and D2 receptor antagonist |
| Aminopyrine | Approved | — | Unknown |
| Amphetamine | Approved | SLC6A3, SLC6A2 | Dopamine transporter releasing agent |
| Antipyrine | Approved | PTGS1 | Cyclooxygenase-1 inhibitor |
| Azathioprine | Approved | PPAT, DNA | Amidophosphoribosyltransferase inhibitor |
| Benzgalantamine | Approved | ACHE | Acetylcholinesterase inhibitor |
| Benzydamine | Approved | PTGS1, PTGS2 | Cyclooxygenase inhibitor |
| Betahistine | Approved | HRH3, HRH1 | Histamine H3 receptor antagonist |
| Broxyquinoline | Approved | — | — |
| Butylscopolamine | Approved | — | — |
| Carbamoylcholine | Approved | CHRM3 | Muscarinic acetylcholine receptor M3 agonist |
| Cephaloridine | Approved | — | — |
| Chlorhexidine | Approved | Cell membrane | Cell membrane inhibitor |
| Chlorpromazine | Approved | HTR2A, D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor antagonist |
| Choline | Approved | — | Diagnostic agent |
| Choline salicylate | Approved | — | Unknown |
| Cycloserine | Approved | DDL, ALR | D-alanylalanine synthetase inhibitor |
| Desvenlafaxine | Approved | SLC6A4, SLC6A2 | Serotonin transporter inhibitor |
| Dexfenfluramine | Approved | Serotonin (5-HT) receptor | Serotonin (5-HT) receptor agonist |
| Dextroamphetamine | Approved | SLC6A3, SLC6A2, SLC18A2 | Dopamine transporter releasing agent |
| Difemerine | Approved | — | Unknown |
| Dihydrocodeine | Approved | OPRM1 | Mu opioid receptor agonist |
| Dopexamine | Approved | — | — |
| Emetine | Approved | — | — |
| Fluciclovine | Approved | — | Diagnostic agent |
| Flupirtine | Approved | — | — |
| Fonazine | Approved | — | — |
| Glucosamine | Approved | — | Supplement |
| Glutamine | Approved | — | Unknown |
| Glymidine | Approved | — | — |
| Hexamidine | Approved | — | — |
| Hyoscyamine | Approved | — | — |
| Inosine | Approved | — | — |
| Isoetharine | Approved | ADRB2 | Beta-2 adrenergic receptor agonist |
| Lidoflazine | Approved | — | — |
| Lumefantrine | Approved | Ferriprotoporphyrin IX | Ferriprotoporphyrin IX inhibitor |
| Medifoxamine | Approved | — | — |
| Mequitazine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Methdilazine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Methenamine | Approved | DNA | DNA inhibitor |
| Methoxyphenamine | Approved | — | — |
| Methylpromazine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Minaprine | Approved | ACHE, DRD1, DRD2, MAOA, CHRM1 and 1 more | Acetylcholinesterase inhibitor |
| Molsidomine | Approved | — | — |
| Muzolimine | Approved | — | Unknown |
| Norepinephrine | Approved | Adrenergic receptor | Adrenergic receptor agonist |
| Oxypertine | Approved | — | — |
| Oxyphenisatine | Approved | — | — |
| Pentamidine | Approved | DNA, Kinetoplast DNA | DNA inhibitor |
| Perhexiline | Approved | CPT1B, CPT2, MTOR | Carnitine O-palmitoyltransferase 1, muscle isoform inhibitor |
| Periciazine | Approved | — | — |
| Phenindamine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Pheniramine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Phenylpropanolamine | Approved | ADRA1A, SLC6A2 | Alpha-1a adrenergic receptor agonist |
| Pholcodine | Approved | — | — |
| Pipotiazine palmitate | Approved | — | — |
| Poldine | Approved | — | — |
| Pramoxine | Approved | — | Unknown |
| Prenylamine | Approved | SCN5A, CALM1 | Sodium channel protein type V alpha subunit blocker |
| Prochlorperazine | Approved | DRD2 | Dopamine D2 receptor antagonist |
| Proxyphylline | Approved | — | — |
| Pyridoxine | Approved | — | Supplement |
| Pyrilamine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Sparteine | Approved | — | Unknown |
| Sulfisomidine | Approved | — | — |
| Terbinafine | Approved | Squalene monooxygenase | Squalene monooxygenase inhibitor |
| Terfenadine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Terodiline | Approved | Muscarinic acetylcholine receptor, Voltage-gated calcium channel | Muscarinic acetylcholine receptor antagonist |
| Tetrahydrozoline | Approved | Adrenergic receptor alpha | Adrenergic receptor alpha agonist |
| Thenalidine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Theophylline anhydrous | Approved | Phosphodiesterase 4, PDE3A, PDE3B, Adenosine receptor | Phosphodiesterase 4 inhibitor |
| Thiamine ion | Approved | — | Supplement |
| Thiethylperazine | Approved | DRD2 | Dopamine D2 receptor antagonist |
| Thioridazine | Approved | HTR2A, HTR2C, D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor antagonist |
| Tisopurine | Approved | — | — |
| Triflupromazine | Approved | DRD2 | Dopamine D2 receptor antagonist |
| Trimetazidine | Approved | — | — |
| Tripelennamine | Approved | HRH1 | Histamine H1 receptor antagonist |
| Tritoqualine | Approved | — | — |
| Trolamine | Approved | — | — |
| Tyrosine | Approved | — | — |
| Venlafaxine | Approved | SLC6A4, SLC6A2 | Serotonin transporter inhibitor |
| Yohimbine | Approved | — | — |
| Zimeldine | Approved | Serotonin (5-HT) receptor | Serotonin (5-HT) receptor antagonist |
| Acadesine | Phase 3 | AMP-activated protein kinase, AMPK | AMP-activated protein kinase, AMPK activator |
| Ademetionine | Phase 3 | — | — |
| Adenine | Phase 3 | — | — |
| Ajmaline | Phase 3 | — | — |
| Alanine | Phase 3 | — | — |
| Amorolfine | Phase 3 | — | — |
| Anisodamine | Phase 3 | — | — |
| Anisodine hydrobromide | Phase 3 | — | — |
| Arundine | Phase 3 | — | — |
| Benfotiamine | Phase 3 | — | — |
| Berberine | Phase 3 | — | — |
| Bicifadine | Phase 3 | Monoamine transporter | Monoamine transporter inhibitor |
| Brilaroxazine | Phase 3 | — | — |
| Bucillamine | Phase 3 | — | Antioxidant |
| Carnitine | Phase 3 | — | — |
| Carnosine | Phase 3 | — | — |
| Choline alfoscerate | Phase 3 | — | — |
| Choline bitartrate | Phase 3 | — | — |
| Citicoline | Phase 3 | — | — |
| Creatine | Phase 3 | — | — |
| Dexmecamylamine | Phase 3 | CHRNA4, CHRNB2 | Neuronal acetylcholine receptor; alpha4/beta2 antagonist |
| Diethylamine | Phase 3 | — | — |
| Dioxydine | Phase 3 | — | — |
| Ethylenediamine | Phase 3 | — | — |
| Etifoxine | Phase 3 | GABA-A receptor; anion channel | GABA-A receptor; anion channel antagonist |
| Hydromethylthionine | Phase 3 | — | — |
| Idalopirdine | Phase 3 | HTR6 | Serotonin 6 (5-HT6) receptor antagonist |
| Indocyanine green acid form | Phase 3 | — | Diagnostic agent |
| Intepirdine | Phase 3 | HTR6 | Serotonin 6 (5-HT6) receptor antagonist |
| Latrepirdine | Phase 3 | — | — |
| Lonidamine | Phase 3 | — | — |
| Lumefantrine co-artemether | Phase 3 | — | — |
| Meglumine antimonate | Phase 3 | — | — |
| Methionine | Phase 3 | — | — |
| Microcrystalline cellulose | Phase 3 | — | — |
| Midomafetamine | Phase 3 | SLC6A3, SLC6A4, SLC6A2 | Sodium-dependent dopamine transporter releasing agent |
| Octaaminoacridine | Phase 3 | — | — |
| Ornithine | Phase 3 | — | — |
| Oxethazaine | Phase 3 | — | — |
| Oxolamine | Phase 3 | — | — |
| Oxomemazine | Phase 3 | — | — |
| Pafuramidine | Phase 3 | Kinetoplast DNA | Kinetoplast DNA inhibitor |
| Pantethine | Phase 3 | — | — |
| Perazine | Phase 3 | — | — |
| Phenazopyridine | Phase 3 | Sodium channel alpha subunit | Sodium channel alpha subunit blocker |
| Phosphatidylcholine | Phase 3 | — | — |
| Phosphine silane | Phase 3 | — | — |
| Polygeline | Phase 3 | — | — |
| Pridopidine | Phase 3 | DRD2 | Dopamine D2 receptor modulator |
| Propamidine | Phase 3 | — | — |
| Putrescine | Phase 3 | — | — |
| Pyrazine | Phase 3 | — | — |
| Pyridoxamine dihydrochloride | Phase 3 | — | — |
| Pyrimidine | Phase 3 | — | — |
| Pyronaridine | Phase 3 | — | — |
| Racemetyrosine | Phase 3 | — | — |
| Selenomethionine | Phase 3 | — | — |
| Sinomenine | Phase 3 | — | — |
| Spermidine | Phase 3 | — | — |
| Squalamine | Phase 3 | SLC9A3 | Sodium/hydrogen exchanger 3 inhibitor |
| Sudapyridine | Phase 3 | — | — |
| Tacedinaline | Phase 3 | Histone deacetylase | Histone deacetylase inhibitor |
| Taurine | Phase 3 | — | — |
| Taurolidine | Phase 3 | Cell wall | Cell wall disrupting agent |
| Theanine | Phase 3 | — | — |
| Theobromine | Phase 3 | — | — |
| Tianeptine | Phase 3 | — | — |
| Tilarginine | Phase 3 | Nitric oxide synthase | Nitric oxide synthase inhibitor |
| Tirapazamine | Phase 3 | DNA | DNA disrupting agent |
| Toludesvenlafaxine | Phase 3 | — | — |
| Trimebutine | Phase 3 | — | — |
| Tyramine | Phase 3 | — | — |
| Uridine | Phase 3 | — | — |
| Uridine triphosphate | Phase 3 | — | — |
| Vanoxerine | Phase 3 | — | — |
| Acepromazine | Phase 2 | — | — |
| Acetylleucine | Phase 2 | — | — |
| Acridine | Phase 2 | DNA | DNA disrupting agent |
| Acyline | Phase 2 | GNRHR | Gonadotropin-releasing hormone receptor antagonist |
| Adenosine triphosphate | Phase 2 | — | — |
| Amitifadine | Phase 2 | Monoamine transporter | Monoamine transporter inhibitor |
| Anabaseine | Phase 2 | — | — |
| Aprindine | Phase 2 | — | — |
| Arginine aspartate | Phase 2 | — | — |
| Arginine butyrate | Phase 2 | — | — |
| Ateganosine | Phase 2 | — | — |
| Atevirdine mesylate | Phase 2 | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Aviscumine | Phase 2 | — | — |
| Benproperine | Phase 2 | — | — |
| Benzoctamine | Phase 2 | — | — |
| Bornaprine | Phase 2 | — | — |
| Bucladesine | Phase 2 | — | — |
| Bunaftine | Phase 2 | — | — |
| Butalamine | Phase 2 | — | — |
| Butaperazine | Phase 2 | — | — |
| Cathine | Phase 2 | — | — |
| Cepharanthine | Phase 2 | — | — |
| Cerlapirdine | Phase 2 | HTR6 | Serotonin 6 (5-HT6) receptor antagonist |
| Chlorbenzoxamine | Phase 2 | — | — |
| Chlorine dioxide | Phase 2 | — | — |
| Chlorophenylpiperazine | Phase 2 | — | — |
| Chloropyramine | Phase 2 | — | — |
| Chlorproethazine | Phase 2 | — | — |
| Chlorsulfaquinoxaline | Phase 2 | — | — |
| Choline magnesium trisalicylate | Phase 2 | — | — |
| Cicletanine | Phase 2 | — | — |
| Cifenline | Phase 2 | — | — |
| Cotinine | Phase 2 | — | — |
| Creatinine | Phase 2 | — | — |
| Cyamemazine | Phase 2 | — | — |
| Cyclopentamine | Phase 2 | — | — |
| Cytosine | Phase 2 | — | — |
| Dehydroemetine | Phase 2 | — | — |
| Demecolcine | Phase 2 | — | — |
| Dersalazine | Phase 2 | — | — |
| Dibrompropamidine | Phase 2 | — | — |
| Diethanolamine | Phase 2 | — | — |
| Diisopromine | Phase 2 | — | — |
| Dimefline | Phase 2 | — | — |
| Dinalbuphine sebacate | Phase 2 | — | — |
| Doxribtimine | Phase 2 | — | — |
| Edelinontrine | Phase 2 | PDE9A | Phosphodiesterase 9A inhibitor |
| Edoxudine | Phase 2 | — | — |
| Eleclazine | Phase 2 | — | — |
| Etilamfetamine | Phase 2 | — | — |
| Fendiline | Phase 2 | — | — |
| Fenethylline | Phase 2 | — | — |
| Forodesine | Phase 2 | PNP | Purine nucleoside phosphorylase inhibitor |
| Hexobendine | Phase 2 | — | — |
| Histapyrrodine | Phase 2 | — | — |
| Huperzine a | Phase 2 | ACHE | Acetylcholinesterase inhibitor |
| Ibogaine | Phase 2 | — | — |
| Immunocytokine NHS-IL12 | Phase 2 | — | — |
| Imolamine | Phase 2 | — | — |
| Irsenontrine | Phase 2 | PDE9A | Phosphodiesterase 9A inhibitor |
| Irsogladine | Phase 2 | — | — |
| Isoxsuprine | Phase 2 | Adrenergic receptor alpha-1, ADRB2 | Adrenergic receptor alpha-1 antagonist |
| Landipirdine | Phase 2 | — | — |
| Lanicemine | Phase 2 | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor blocker |
| Leucine | Phase 2 | — | — |
| Linopirdine | Phase 2 | — | — |
| Linsidomine | Phase 2 | — | — |
| Lobeline | Phase 2 | — | — |
| Lorajmine | Phase 2 | — | — |
| Lysine | Phase 2 | — | Radioprotective agent |
| Maritupirdine | Phase 2 | — | — |
| Masupirdine | Phase 2 | HTR6 | Serotonin 6 (5-HT6) receptor antagonist |
| Meglumine | Phase 2 | — | — |
| Meladrazine | Phase 2 | — | — |
| Methoserpidine | Phase 2 | — | — |
| Methoxyamine | Phase 2 | — | — |
| Metizoline | Phase 2 | — | — |
| Metopimazine | Phase 2 | — | — |
| Monoethanolamine | Phase 2 | — | — |
| Moroxydine | Phase 2 | — | — |
| Nerispirdine | Phase 2 | Voltage-gated potassium channel, Sodium channel alpha subunit | Voltage-gated potassium channel blocker |
| Osoresnontrine | Phase 2 | PDE9A | Phosphodiesterase 9A inhibitor |
| Oxazolidine | Phase 2 | — | — |
| Perphenazine 4-aminobutyrate | Phase 2 | — | — |
| Phosphorylethanolamine | Phase 2 | — | — |
| Picloxydine | Phase 2 | — | — |
| Piperine | Phase 2 | — | — |
| Piromelatine | Phase 2 | MTNR1A, MTNR1B | Melatonin receptor agonist |
| Pizotyline | Phase 2 | — | — |
| Prenoxdiazine | Phase 2 | — | — |
| Proflavine | Phase 2 | DNA | DNA disrupting agent |
| Pyrazoloacridine | Phase 2 | — | — |
| Pyridoxamine | Phase 2 | — | — |
| Quifenadine | Phase 2 | — | — |
| Radafaxine | Phase 2 | — | — |
| Rezatomidine | Phase 2 | — | — |
| Rolusafine | Phase 2 | — | — |
| Sarcosine | Phase 2 | — | — |
| Sequifenadine | Phase 2 | — | — |
| Serine | Phase 2 | — | — |
| Sulcardine | Phase 2 | — | — |
| Sutidiazine | Phase 2 | — | — |
| Talviraline | Phase 2 | — | — |
| Tetrahydropalmatine | Phase 2 | — | — |
| Theodrenaline | Phase 2 | — | — |
| Thioproperazine | Phase 2 | — | — |
| Thonzylamine | Phase 2 | — | — |
| Tilidine | Phase 2 | — | — |
| Tipepidine | Phase 2 | — | — |
| Tocladesine | Phase 2 | — | — |
| Tovinontrine | Phase 2 | PDE9A | Phosphodiesterase 9A inhibitor |
| Trenibotulinumtoxine | Phase 2 | SNAP25 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme |
| Ulodesine | Phase 2 | PNP | Purine nucleoside phosphorylase inhibitor |
| Visnadine | Phase 2 | — | — |
| Zolimidine | Phase 2 | — | — |
| Alanosine | Phase 1 | — | — |
| Alethine | Phase 1 | — | — |
| Apomine | Phase 1 | — | — |
| Berberine ursodeoxycholate | Phase 1 | — | — |
| Buthionine sulfoximine | Phase 1 | — | — |
| Detrothyronine | Phase 1 | — | — |
| Dibutepinephrine | Phase 1 | — | — |
| Diethylhomospermine | Phase 1 | — | — |
| Dihydrexidine | Phase 1 | — | — |
| Doxecitine | Phase 1 | — | — |
| Duocarmazine | Phase 1 | — | — |
| Harmine | Phase 1 | — | — |
| Hydroxynorketamine, (2R,6R) | Phase 1 | — | — |
| Intermedine | Phase 1 | — | — |
| Intoplicine | Phase 1 | — | — |
| Norleucine | Phase 1 | — | — |
| Oleylphosphocholine | Phase 1 | — | — |
| Ordopidine | Phase 1 | DRD2 | Dopamine D2 receptor modulator |
| Orellanine | Phase 1 | — | — |
| Peldesine | Phase 1 | — | — |
| Penclomedine | Phase 1 | — | — |
| Phenylalanine | Phase 1 | — | — |
| Pimagedine | Phase 1 | — | — |
| Tasipimidine | Phase 1 | ADRA2A | Alpha-2A adrenergic receptor agonist |
| Trodusquemine | Phase 1 | — | — |
| Florbenazine | Early phase 1 | — | — |
| Hydrazine | Early phase 1 | — | — |
| Racepinephrine | Early phase 1 | — | — |
| Spermine | Early phase 1 | — | — |
| Valine | Early phase 1 | — | — |
| Acetyldihydrocodeine | — | — | — |
| Adoprazine | — | HTR1A, DRD2, DRD3 | Serotonin 1a (5-HT1a) receptor agonist |
| Azapetine | — | — | — |
| Bovine concentrated lactoserum containing specific immunoglobulins g against e. coli F5 (K99) adhesin | — | — | Bovine colostrum containing protective antibodies |
| Calamine | — | — | Unknown |
| Canine parainfluenza TYPE-2 virus, strain CPIV-2 bio 15 (live attenuated) | — | — | Biological vaccine - induces immune response |
| Canine parainfluenza virus, leptospira and rabies virus | — | — | Biological vaccine - induces immune response |
| Chlornaphazine | — | — | — |
| Delucemine | — | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor antagonist |
| Desfesoterodine | — | — | — |
| Dibromotyrosine | — | — | — |
| Dihydroergocristine | — | — | — |
| Dihydroergocryptine | — | — | — |
| Dimethylaminopropionylphenothiazine | — | — | — |
| Diotyrosine | — | — | — |
| Diphenhydramine methylbromide | — | — | — |
| Dithiazanine | — | — | — |
| Dixyrazine | — | — | — |
| Etanautine | — | — | — |
| Feline interleukin-2 recombinant canarypox virus (VCP1338 virus) | — | — | Biological vaccine - induces immune response |
| Fursultiamine | — | — | Supplement |
| Fusafungine | — | — | — |
| Gallamine | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Hydroxyethylpromethazine | — | — | — |
| Hydroxystilbamidine | — | DNA, RNA | DNA inhibitor |
| Isaxonine | — | — | Unknown |
| Levamfetamine | — | — | — |
| Mebanazine | — | MAOA, MAOB | Monoamine oxidase inhibitor |
| Mepazine | — | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 inhibitor |
| Methopholine | — | — | Unknown |
| Metocurine | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Neboglamine | — | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor positive allosteric modulator |
| Olanexidine | — | Cell membrane | Cell membrane disrupting agent |
| Oxyquinoline | — | — | — |
| Phenoxypropazine | — | MAOA, MAOB | Monoamine oxidase inhibitor |
| Pipamazine | — | — | Unknown |
| Piperazine citrate anhydrous | — | Nematode GABA-A receptor | Nematode GABA-A receptor positive modulator |
| Pyrrobutamine | — | — | — |
| Seridopidine | — | DRD2 | Dopamine D2 receptor modulator |
| Tenitramine | — | — | — |
| Trimethyldiphenylpropylamine | — | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO